{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 0.0, "regularMarketPrice": 3.67, "exchange": "NMS", "shortName": "Opthea Limited", "longName": "Opthea Limited", "messageBoardId": "finmb_2482138", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1602855000000, "priceHint": 4, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.41, "sharesOutstanding": 58364800, "bookValue": 0.968, "fiftyDayAverage": 3.96282, "fiftyDayAverageChange": -0.29281998, "fiftyDayAverageChangePercent": -0.07389182, "twoHundredDayAverage": 5.09798, "twoHundredDayAverageChange": -1.42798, "twoHundredDayAverageChangePercent": -0.28010702, "marketCap": 214198816, "priceToBook": 3.7913225, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "averageAnalystRating": "1.4 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": 0.0, "regularMarketTime": 1684166318, "regularMarketDayHigh": 3.67, "regularMarketDayRange": "3.67 - 3.67", "regularMarketDayLow": 3.67, "regularMarketVolume": 1938, "regularMarketPreviousClose": 3.67, "bid": 3.7, "ask": 3.76, "bidSize": 8, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 3.73, "averageDailyVolume3Month": 8375, "averageDailyVolume10Day": 5820, "fiftyTwoWeekLowChange": 0.42200017, "fiftyTwoWeekLowChangePercent": 0.12992616, "fiftyTwoWeekRange": "3.248 - 8.5", "fiftyTwoWeekHighChange": -4.83, "fiftyTwoWeekHighChangePercent": -0.5682353, "fiftyTwoWeekLow": 3.248, "fiftyTwoWeekHigh": 8.5, "displayName": "Opthea", "symbol": "OPT"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "650 Chapel Street", "address2": "Suite 0403 Level 4", "city": "South Yarra", "state": "VIC", "zip": "3141", "country": "Australia", "phone": "61 3 9826 0399", "fax": "61 3 9824 0083", "website": "https://opthea.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Megan  Baldwin M.A.I.C.D., MAICD, Ph.D.", "age": 48, "title": "MD, CEO & Exec. Director", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 490236, "fmt": "490.24k", "longFmt": "490,236"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 398667, "fmt": "398.67k", "longFmt": "398,667"}}, {"maxAge": 1, "name": "Ms. Judith J. Robertson B.A., M.B.A.", "age": 62, "title": "Chief Commercial Officer", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 495500, "fmt": "495.5k", "longFmt": "495,500"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Joel  Naor M.D., MBA, MSc", "title": "Chief Medical Officer", "fiscalYear": 2022, "totalPay": {"raw": 492750, "fmt": "492.75k", "longFmt": "492,750"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Karen  Adams CPA", "age": 51, "title": "VP of Fin. & Company Sec.", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 260120, "fmt": "260.12k", "longFmt": "260,120"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy E. Morris CPA, CPA", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Annie  Lee", "title": "Fin. & Operations Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Gerometta Ph.D.", "age": 58, "title": "Head of Chemistry, Manufacturing & Controls Devel.", "yearBorn": 1964, "fiscalYear": 2014, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bruno  Gagnon BPHARM, M.Sc.", "title": "Sr. VP of Global Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}